Menopause is a natural biological process that marks the end of a woman's reproductive years, typically occurring around the age of 50 [4]. This transition is characterized by significant hormonal changes, primarily a decline in estrogen, which can lead to a wide range of symptoms and affect various aspects of health [3]. While many women experience common symptoms like hot flashes and night sweats, the impact of menopause extends to cardiovascular health, joint conditions, and even migraine patterns [1, 2, 3, 8]. Understanding these changes and the available management options, including hormone therapy and newer treatments, is crucial for maintaining well-being during this life stage.
Common Menopausal Symptoms
Approximately 75% of women aged 45 to 55 years experience menopausal symptoms [1]. These can be diverse and include:
- Vasomotor Symptoms: Hot flashes and night sweats are among the most recognized symptoms [1].
- Sleep Disturbances: Insomnia is a common complaint [1].
- Headaches: Migraines can be affected by hormonal fluctuations during perimenopause, with some women experiencing changes in migraine characteristics or onset during this period [1, 8].
- Genitourinary Symptoms: These can include vaginal dryness and discomfort [6].
- Fatigue and Palpitations: These symptoms can overlap with those of heart conditions, making diagnosis challenging [3].
It's important to note that some menopausal symptoms, such as fatigue, shortness of breath, sleep disturbance, and palpitations, can also be signs of underlying cardiac pathology, highlighting the need for careful evaluation [3].
Hormone Therapy and Its Considerations
Hormone therapy (HT), primarily involving estrogen replacement, is a common treatment for menopausal symptoms. Estrogen plays a role in various bodily functions, including cardioprotection through anti-inflammatory and vasodilatory pathways [3]. However, the effects of HT can vary depending on the individual's health profile and specific conditions [4].
- Symptom Relief: HT can be effective in alleviating vasomotor symptoms like hot flashes and night sweats [1].
- Cardiovascular Health: The decline in estrogen during menopause has been linked to an increased risk of heart failure, and early menopause independently predicts this risk [3]. HT's impact on cardiovascular health is complex and needs to be considered individually [3].
- Rheumatic Diseases: The relationship between menopause, estrogen, and rheumatic conditions like osteoarthritis, rheumatoid arthritis, and systemic lupus erythematosus is well-documented. HT's effects on these conditions can be beneficial or detrimental, depending on the specific disease and its manifestations [2, 4].
- Risks and Contraindications: HT may not be suitable for everyone. For example, some women with migraine may find that oral estradiol worsens their headaches [1]. Obesity can also alter the risk profile of menopausal hormone therapy, particularly increasing the risk of thromboembolic events with oral formulations [6].
Emerging and Alternative Treatments
For women who cannot use or prefer not to use traditional hormone therapy, other options are being explored:
- Fezolinetant: This is a neurokinin-3 receptor antagonist approved for treating menopausal vasomotor symptoms [5]. Real-world safety data for fezolinetant are being collected to understand its profile better [5].
- Lamotrigine: A case report described a woman whose menopausal hot flashes, night sweats, and insomnia disappeared after starting lamotrigine, a medication primarily used for epilepsy and bipolar disorder, and off-label for migraine prevention [1]. Her symptoms returned when she stopped the medication [1]. While promising, this is a single case report, and more research is needed [1].
Holistic Approach to Menopause Management
Managing menopause often requires a comprehensive approach that goes beyond just hormone therapy:
- Obesity Management: Obesity is common during the menopausal transition and can worsen vasomotor and genitourinary symptoms [6]. It also increases the thromboembolic risk associated with oral hormone therapy [6]. Integrating obesity management strategies with menopause care can improve metabolic outcomes, relieve symptoms, and lower long-term cardiovascular and oncologic risks [6].
- Thyroid Health: Thyroid diseases are common in women in their late reproductive years and can coexist with menopause, presenting with overlapping symptoms that make diagnosis challenging [7]. Healthcare professionals need to be aware of this overlap for accurate diagnosis and personalized treatment [7].
- Personalized Care: Given the varied symptoms and individual health profiles, a personalized approach to menopause management is essential. This involves careful consideration of a woman's specific characteristics, symptom severity, existing health conditions, and preferences when making treatment decisions [7].
It is crucial for women experiencing menopausal symptoms to discuss their concerns with a healthcare provider to receive an accurate diagnosis and develop an individualized management plan.
Sources
- [1] Menopausal hot flashes, night sweats, and insomnia disappeared with lamotrigine: a case report. https://pubmed.ncbi.nlm.nih.gov/41401224/
- [2] Menopause, oestrogens and arthritis. https://pubmed.ncbi.nlm.nih.gov/10936736/
- [3] Overlap Between Heart Failure and Menopause: Diagnostic Challenges and Clinical Implications. https://pubmed.ncbi.nlm.nih.gov/42463399/
- [4] Menopause and Rheumatic Disease. https://pubmed.ncbi.nlm.nih.gov/28390570/
- [5] Real-world safety signals of fezolinetant in women with menopausal vasomotor symptoms: a pharmacovigilance analysis of the WHO VigiAccess database. https://pubmed.ncbi.nlm.nih.gov/42610452/
- [6] Integrating obesity management into menopause care recommendations comments on the 2025 European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. https://pubmed.ncbi.nlm.nih.gov/41467347/
- [7] EMAS position statement: Thyroid disease and menopause. https://pubmed.ncbi.nlm.nih.gov/38658290/
- [8] Clinical characteristics of perimenopausal migraine and its correlation to hormonal levels. https://pubmed.ncbi.nlm.nih.gov/42304215/